What do the numbers say about Amrutanjan Health Care Limited (AMRUTANJAN)? Here's a look at its financials, valuation, and ownership data.
Amrutanjan Revenue Trend
Amrutanjan Health Care Limited's top line grew 7.1% to ₹469 Cr in FY2025, compared to ₹438 Cr in FY2024.
Over the past 10 years, revenue has grown at a healthy 10.9% CAGR, from ₹167 Cr to ₹469 Cr. That's solid, above-average growth.
With a top line of ₹469 Cr, Amrutanjan Health Care Limited operates at a smaller scale within the pharmaceuticals sector.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹469 Cr | +7.1% |
| FY2024 | ₹438 Cr | +11.2% |
| FY2023 | ₹394 Cr | -6.4% |
| FY2022 | ₹421 Cr | +26.6% |
| FY2021 | ₹333 Cr | — |
View Amrutanjan Health Care Limited's full 10-year revenue trend with CAGR analysis →
Amrutanjan Profitability
Amrutanjan Health Care Limited turned in a net profit of ₹50.8 Cr for FY2025. That's 13.0% better than the ₹45.0 Cr earned in FY2024.
The company maintained its net margin at 10.8% in FY2025, roughly in line with the prior year.
FY2025 diluted EPS of ₹17.58 was up from the ₹15.56 reported in FY2024.
Is Amrutanjan Undervalued
Based on the P/E Ratio model, Amrutanjan Health Care Limited's fair value works out to ₹708 — 29.5% upside from where it trades today.
Amrutanjan Health Care Limited shares are currently trading at ₹546.55.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹708 | 29.5% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Amrutanjan Health Care Limited with detailed assumptions →
Amrutanjan Shareholding Pattern
Promoters continue to hold 46.5% of the company, unchanged over recent quarters.
FII holding stands at 2.2%, down from 2.4% in the year-ago quarter.
Domestic institutions moved their stake down to 12.7% from 12.7% over the past year.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 46.5% | 2.2% | 12.7% | 38.6% |
| Dec 2025 | 46.5% | 2.3% | 13.0% | 38.2% |
| Sep 2025 | 46.5% | 2.4% | 12.9% | 38.2% |
| Jun 2025 | 46.5% | 2.4% | 12.7% | 38.3% |
Track quarterly shareholding changes for Amrutanjan Health Care Limited →
Amrutanjan Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹4.21B (up 14.9% YoY from ₹3.67B).
Top categories: Other Assets (62.7%), Property, Plant & Equipment (14.7%), Receivables (13.2%).
Of the ₹4.21B in liabilities and equity, 77.5% is shareholder equity, 0.5% is interest-bearing debt, and 22.0% is operating liabilities. Over the year, debt is up 20.2% and equity is up 13.2%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 101.55M |
| Receivables | 558.22M |
| Inventories | 272.60M |
| Property, Plant & Equipment | 620.43M |
| Investments | 451,000 |
| Intangibles & Goodwill | 16.78M |
| Other Assets | 2.64B |
| Category | Value |
|---|---|
| Equity | 3.27B |
| Short-term Debt | 4.02M |
| Long-term Debt | 16.76M |
| Trade Payables | 690.43M |
| Other Liabilities | 236.52M |
What Stands Out About Amrutanjan
Bringing the key threads together for Amrutanjan Health Care Limited (AMRUTANJAN) as a pharmaceuticals investment opportunity.
Revenue of ₹469 Cr in FY2025, up 7.1% year-over-year.
Long-term revenue has been compounding at 10.9% annually over 10 years.
The company is profitable, with a net margin of 10.8% and net income of ₹50.8 Cr.
The P/E Ratio model implies 29.5% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Amrutanjan Health Care Limited's detailed profile on Craytheon.